Vijaya Diagnostic (VIJAYA) | Financial Analysis & Statements
Vijaya Diagnostic Centre Ltd. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
1.9B
Gross Profit
1.7B
88.61%
Operating Income
526.4M
27.99%
Net Income
385.9M
20.52%
EPS (Diluted)
₹3.75
Balance Sheet Metrics
Total Assets
12.7B
Total Liabilities
4.7B
Shareholders Equity
8.0B
Debt to Equity
0.59
Cash Flow Metrics
Operating Cash Flow
282.3M
Free Cash Flow
-321.8M
Revenue & Profitability Trend
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Vijaya Diagnostic Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 6.8B | 5.5B | 4.6B | 4.6B | 3.8B |
| Cost of Goods Sold | 847.6M | 654.4M | 588.8M | 715.0M | 570.9M |
| Gross Profit | 6.0B | 4.8B | 4.0B | 3.9B | 3.2B |
| Gross Margin % | 87.6% | 88.0% | 87.2% | 84.5% | 84.8% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 1.3B | 988.8M | 781.7M | 669.0M | 517.3M |
| Other Operating Expenses | 830.3M | 711.4M | 605.2M | 484.6M | 432.6M |
| Total Operating Expenses | 2.1B | 1.7B | 1.4B | 1.2B | 949.9M |
| Operating Income | 2.0B | 1.6B | 1.2B | 1.5B | 1.2B |
| Operating Margin % | 29.8% | 29.9% | 26.2% | 32.7% | 30.8% |
| Non-Operating Items | |||||
| Interest Income | 57.6M | 59.7M | 82.8M | 98.0M | 96.0M |
| Interest Expense | 245.5M | 219.6M | 194.2M | 152.1M | 135.1M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 1.9B | 1.6B | 1.1B | 1.5B | 1.1B |
| Income Tax | 493.7M | 390.4M | 283.0M | 367.2M | 270.0M |
| Effective Tax Rate % | 25.6% | 24.6% | 24.9% | 24.9% | 24.1% |
| Net Income | 1.4B | 1.2B | 852.1M | 1.1B | 851.3M |
| Net Margin % | 21.1% | 21.8% | 18.6% | 23.9% | 22.6% |
| Key Metrics | |||||
| EBITDA | 2.8B | 2.3B | 1.9B | 2.1B | 1.8B |
| EPS (Basic) | ₹13.95 | ₹11.62 | ₹8.29 | ₹10.76 | ₹8.28 |
| EPS (Diluted) | ₹13.92 | ₹11.59 | ₹8.26 | ₹10.69 | ₹8.28 |
| Basic Shares Outstanding | 102587847 | 102221031 | 102041263 | 101965926 | 101965926 |
| Diluted Shares Outstanding | 102587847 | 102221031 | 102041263 | 101965926 | 101965926 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Vijaya Diagnostic Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 127.9M | 222.4M | 241.7M | 110.5M | 66.9M |
| Short-term Investments | 2.7B | 1.6B | 2.3B | 2.1B | 2.1B |
| Accounts Receivable | 147.6M | 162.4M | 94.9M | 97.7M | 67.0M |
| Inventory | 49.3M | 51.8M | 20.5M | 42.8M | 26.4M |
| Other Current Assets | 62.5M | 45.7M | 50.9M | 41.0M | -400.0K |
| Total Current Assets | 3.1B | 2.1B | 2.8B | 2.7B | 2.4B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 314.9M | 258.9M | 211.4M | 145.8M | 106.6M |
| Goodwill | 2.6B | 2.6B | 135.0M | 121.0M | 125.1M |
| Intangible Assets | 218.9M | 211.8M | 28.3M | 14.3M | 18.4M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 136.2M | 61.9M | 86.2M | 222.8M | -100 |
| Total Non-Current Assets | 9.7B | 7.7B | 5.8B | 4.4B | 3.0B |
| Total Assets | 12.7B | 9.8B | 8.5B | 7.1B | 5.4B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 331.3M | 329.5M | 277.1M | 216.4M | 221.6M |
| Short-term Debt | 231.6M | 201.3M | 145.3M | 132.0M | 113.0M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 40.1M | 35.3M | 31.9M | 36.1M | 30.2M |
| Total Current Liabilities | 1.6B | 728.7M | 661.7M | 661.2M | 442.9M |
| Non-Current Liabilities | |||||
| Long-term Debt | 3.0B | 2.4B | 2.3B | 1.7B | 1.3B |
| Deferred Tax Liabilities | 52.8M | - | - | - | - |
| Other Non-Current Liabilities | 3.0M | 3.4M | 4.6M | 1.2M | 2.2M |
| Total Non-Current Liabilities | 3.1B | 2.5B | 2.4B | 1.8B | 1.4B |
| Total Liabilities | 4.7B | 3.2B | 3.1B | 2.4B | 1.8B |
| Equity | |||||
| Common Stock | 102.6M | 102.3M | 102.1M | 102.0M | 45.3M |
| Retained Earnings | 7.2B | 5.9B | 4.8B | 4.1B | 3.0B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 8.0B | 6.6B | 5.5B | 4.7B | 3.6B |
| Key Metrics | |||||
| Total Debt | 3.2B | 2.6B | 2.5B | 1.8B | 1.4B |
| Working Capital | 1.4B | 1.4B | 2.1B | 2.0B | 1.9B |
Balance Sheet Composition
Vijaya Diagnostic Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 1.9B | 1.6B | 1.1B | 1.5B | 1.1B |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | 15.9M | 9.3M | 7.2M | 11.4M | 2.0M |
| Working Capital Changes | -91.5M | -58.5M | 10.2M | -81.2M | -47.8M |
| Operating Cash Flow | 2.0B | 1.7B | 1.3B | 1.5B | 1.1B |
| Investing Activities | |||||
| Capital Expenditures | -926.1M | -846.3M | -1.2B | -1.2B | -312.3M |
| Acquisitions | 0 | -1.5B | 0 | -17.0M | 0 |
| Investment Purchases | -1.5B | - | -800.4M | -247.7M | -1.3B |
| Investment Sales | 585.4M | 824.7M | 886.9M | 120.8M | 275.3M |
| Investing Cash Flow | -1.9B | -1.5B | -1.2B | -1.4B | -1.3B |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | -102.6M | -102.3M | -102.1M | - | - |
| Debt Issuance | - | - | - | - | 0 |
| Debt Repayment | - | 0 | -6.3M | -38.4M | -282.6M |
| Financing Cash Flow | -61.6M | -71.8M | -103.2M | -44.0M | -283.7M |
| Free Cash Flow | 1.3B | 953.4M | 397.7M | 356.5M | 975.1M |
| Net Change in Cash | 127.6M | 128.6M | -7.7M | 58.8M | -529.5M |
Cash Flow Trend
Vijaya Diagnostic Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
67.41
Forward P/E
50.66
Price to Book
12.37
Price to Sales
13.94
PEG Ratio
25.06
Profitability Ratios
Profit Margin
20.73%
Operating Margin
30.07%
Return on Equity
17.90%
Return on Assets
11.23%
Financial Health
Current Ratio
1.89
Debt to Equity
42.22
Beta
0.01
Per Share Data
EPS (TTM)
₹15.44
Book Value per Share
₹84.14
Revenue per Share
₹74.83
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| VIJAYA | 109.6B | 67.41 | 12.37 | 17.90% | 20.73% | 42.22 |
| Dr. Lal PathLabs | 238.9B | 46.16 | 10.20 | 22.08% | 19.84% | 6.44 |
| Sai Life Sciences | 217.1B | 64.75 | 9.48 | 7.99% | 15.34% | 18.40 |
| Syngene | 169.3B | 48.19 | 3.57 | 10.50% | 9.47% | 12.28 |
| Metropolis | 97.9B | 58.44 | 6.85 | 10.86% | 10.74% | 13.92 |
| Thyrocare | 62.9B | 45.42 | 11.76 | 16.73% | 17.35% | 4.62 |
Financial data is updated regularly. All figures are in the company's reporting currency.





